Article

Dose of approved COVID-19 vaccines is based on weak evidence: a review of early-phase, dose-finding trials

2022-09-22

Abstract excerpt

<h4>ABSTRACT</h4> Although over 12 billion COVID-19 vaccine doses have been administered globally, the important issue of whether the optimal doses are being used has been relatively neglected. To address this question, we reviewed the reports of early-phase dose-finding trials of the nine COVID-19 vaccines approved by World Health Organization (and one additional vaccine which showed partial clinical efficacy), e...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a6fa0777-fe60-5929-ba2f-1c2516d66501
DOI: 10.1101/2022.09.20.22276701

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Dose of approved COVID-19 vaccines is based on weak evidence: a review of early-phase, dose-finding trialsDOI 10.1101/2022.09.20.22276701Read

Nature Of, Immune Reaction to and Side Effects of COVID-19 Vaccines: Synthesis of Information Including Exclusions from Ten Phase II Trials for Planning Vaccination ProgrammesSemantic proximity Read

COVID-19 vaccines: breaking record times to first-in-human trialsSemantic proximity Read

Efficacy Estimates for Various COVID-19 Vaccines: What we Know from the Literature and ReportsSemantic proximity Read

An objective systematic comparison of the most common adverse events of COVID-19 vaccinesSemantic proximity Read

Evidence for antibody as a protective correlate for COVID-19 vaccinesSemantic proximity Read

Review on different COVID-19 vaccines approved for Emergency Use Listing by WHO until 11 July 2022: characterization, pharmacological properties, mechanism of action and adverse events.Semantic proximity Read

SAFETY AND IMMUNOGENICITY OF A PHH-1V BOOSTER DOSE AFTER DIFFERENT PRIME VACCINATION SCHEMES AGAINST COVID-19: PHASE III CLINICAL TRIAL FINAL RESULTS UP TO ONE YEARSemantic proximity Read

Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trialSemantic proximity Read

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised phase III clinical studySemantic proximity Read

Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines.Semantic proximity Read

An Immunobridging study to evaluate the neutralizing antibody titer in adults immunized with two doses of either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901Semantic proximity Read

Safety and Immunogenicity of Fractional Doses of COVID-19 Vaccines among Nigerian Adults- A Randomised Non-Inferiority trialSemantic proximity Read